4,7-二羟基-3-喹啉羧酸乙酯 | 104047-30-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4,7-二羟基-3-喹啉羧酸乙酯
• 中文别名: 4,7-二羟基喹啉-3-羧酸乙酯
• 英文名称: 4,7-dihydroxy-3-quinolinecarboxylic acid ethyl ester
• 英文别名: 4,7-dihydroxyquinoline-3-carboxylic acid ethyl ester；Ethyl 4,7-dihydroxyquinoline-3-carboxylate；ethyl 7-hydroxy-4-oxo-1H-quinoline-3-carboxylate
• CAS: 104047-30-5
• 化学式: C₁₂H₁₁NO₄
• 分子量: 233.224
• InChiKey: FLUZKLSNPUDHBL-UHFFFAOYSA-N

物化性质

• 沸点：
  396.1±37.0 °C(Predicted)
• 密度：
  1.387±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  4,7-二羟基-3-喹啉羧酸乙酯 在 四(三苯基膦)钯 、 caesium carbonate 、 溶剂黄146 、 间氯过氧苯甲酸 、 三氯氧磷 、 三溴氧磷 作用下， 以 1,4-二氧六环 、 氯仿 、 水 为溶剂， 反应 10.0h， 生成 ethyl 2-([1,1'-biphenyl]-3-yl)-7-hydroxy-4-oxo-1,4-dihydroquinoline-3-carboxylate
  参考文献：
  名称：

  Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials

  摘要：

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.

  DOI：

  10.1021/jm201642z
• 作为产物：
  描述：

  1,3-diethyl 2-(((3-hydroxyphenyl)amino)methylidene)propanedioate 以 二苯醚 为溶剂， 生成 4,7-二羟基-3-喹啉羧酸乙酯
  参考文献：
  名称：

  Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials

  摘要：

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.

  DOI：

  10.1021/jm201642z

文献信息

• 一种四环喹啉酮生物碱衍生物及其制备方法和应用
  申请人：中国海洋大学

  公开号：CN108623590A

  公开（公告）日：2018-10-09

  本发明涉及一类四环喹啉酮生物碱衍生物,或其互变异构体、立体异构体、外消旋体、对映异构体的非等量混合物、几何异构体、溶剂化物、药学上可接受的盐或前药,以及包含该化合物的药物组合物。本发明还公开了这类化合物及其药物组合物作为药物,尤其是作为抗病毒、抗菌及抗寄生虫药物的用途。
• Lead Optimization of 3-Carboxyl-4(1<i>H</i>)-Quinolones to Deliver Orally Bioavailable Antimalarials
  作者：Yiqun Zhang、Julie A. Clark、Michele C. Connelly、Fangyi Zhu、Jaeki Min、W. Armand Guiguemde、Anupam Pradhan、Lalitha Iyer、Anna Furimsky、Jason Gow、Toufan Parman、Farah El Mazouni、Margaret A. Phillips、Dennis E. Kyle、Jon Mirsalis、R. Kiplin Guy

  DOI：10.1021/jm201642z

  日期：2012.5.10

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.